medigraphic.com
ISSN 0016-3813 (Impreso)

2003, Número 2

<< Anterior Siguiente >>

Gac Med Mex 2003; 139 (2)


Actualizacion en hemostasia y trombosis

I. Bases de la hemostasia y trombosis
II. Fisiología y regulación de las proteasas de la pared vascular
III. Actualización en purpura trombocitopenica trombotica
IV. Actualidades en el tratamiento de la hemofilia
V. Diagnóstico de la enfermedad de von Willebrand en México
VI. Síndrome antifosfolipido en niños
VII.Alteraciones trombogenicas en la enfermedad arterial coronaria
VIII.Coagulación intravascular diseminada
IX.Factor tisular como marcador de progresión en cáncer
X.La realidad de la prevalencia de la trombosis

Martínez-Murillo C, González-Sandra Q, Tabeada-Meza C, Benítez-Aranda H, López-Santiago N, Izaguirre-Avila R, Paredes-Aguilera R, Majluf-Cruz A

Idioma: Español
Referencias bibliográficas: 180
Paginas: 28-68
Archivo PDF: 578.27 Kb.


FRAGMENTO

La hemostasia es un mecanismo fisiológico para mantener en un estado líquido a la sangre. La coagulación de la sangre es mediada por componentes celulares y proteínas plasmáticas solubles. En respuesta al daño vascular, las plaquetas circulantes se adhieren, agregan y proveen de una superficie celular para la unión de complejos enzimáticos de la coagulación sanguínea.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gaetano G. Historical review of the role of platelets in hemostasis and thrombosis. Haematologica 2001;86:349-356.

  2. Buckwalter JA, Blythe WB, Brinkhous KM. Effect of blood platelets on prothrombin utilization of dog and human plasms. Am J Physiol 1949;159:322-331.

  3. Martínez-Murillo C. Fisiología de la Hemostasia Primaria En: Manual de Hemostasia y Trombosis. 1996.

  4. Rozman P. Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and trasplantation. Trasplant Immunol 2002;10:165-181.

  5. Nemerson Y, Giesen PL. Some thoughts about localization and expression of tissue factor. Blood Coagul Fibrinolysis 1988;1:S45-S47.

  6. Quintana GS, Martínez-Murillo C, Ambriz FR. Fisiología de la Coagulación, En: Hemofilia, Martínez-Murillo, Quintana GS, Ambriz FR y Kasper C..Editorial Prado 2001:19-42.

  7. Lorand L. Szol Sherry lecture in thrombosis: research on clot stabilization provides clues for improving thrombolytic therapies. Arerioescler Thromb Vasc Biol 2000;20:2-9.

  8. Davey M, Luscher E. Actions of thrombin and other coagulant and other coagulant and proteolytic enzymes on blood platelets. Nature 1967;216:857-858.

  9. Esmon C. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-4746.

  10. Bajzar L, Manual R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.

  11. Coughlin S. How thrombin “talks” to cells. Molecular mechanisms and roles in vivo. Arterioscler Thromb Vasc Biol 1998;18:514-518.

  12. Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984;74:1-6.

  13. Rosenberg RD. Vascular-bed-specific hemostasis and hypercoagulable states: Clinical utility of activation peptide assays in predicting thrombotic events in different clinical populations. Thromb Haemost 2001;86:41-50.

  14. Crowter and Kelton. Ann Intern Med 2003:138:128.

  15. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkie BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cell in Physiology and in Pathophysiology of Vascular Disorders. Blood 1998;91:3527.

  16. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898.

  17. Levin ER. Endothelins. N Engl J Med 1996:333:356.

  18. Chen X-S, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1992;372:179.

  19. Bombeli T, Meller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997;77:408.

  20. Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. Nature 1984;74:1.

  21. Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecule from vascular tissue. Biochemistry 1984;23:1730.

  22. Broze GJ Jr. Tissue factor pathway inhibitor. Throm Haemost 1995;74:90.

  23. Esmon CT, Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 1995;6:259.

  24. Fukudome K, Kurosawa S, Stearns-Kurosawa D-J, He X, Rezai AR, Esmon CT. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 1996; 271:17491.

  25. Zucker S, Mirza H, Conner CE. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase-A activation and Cell proliferation. Int J Cancer 1998;75:780.

  26. Kanthou C, Benzakour O. Cellular effects of thrombin and their signaling pathways. Cell Pharmacol 1995;2:293.

  27. Garcia JGN, Pavalko FM, Patterson CE. Vascular endothelial cell activation and permeability responses to thrombin. Blood Coag Fibrinol 1995;6:609.

  28. Ishihara H, Connoly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. 1997;386:502.

  29. Wagner DD, Bonfanti R. von Willebrand factor and the endothelium. Mayo Clin Proc 1991;66:62.

  30. Moschcovitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of terminal arteriols and capillaries: An undescribed disease. Arch Intern Med 1925;36:89-92.

  31. Baer G, Klemperer P, Schifin A. An acute febrile anemia with thrombocytopenic purpura with difuse platelet thrombosis of capillaires and arterioles. Trans Asocc Am Physicians 1936;65:43-47.

  32. Gautier E, Siebenmann RE. The birth of the hemolytic uremic syndrome, in Hemolytic Uremic Syndrome and Thrombotyc Thrombocytopenic Purpura, edited by BS Kaplan, RS Trompeter, JL Moake. Marcel Dekker, ew York. 1992, pp 1-17.

  33. Amorosi EL, Ultmann JE. Thrombotic Thrombocytopenic Purpura: report of 16 cases and review of the literature. Medicine 1966;45:139-144.

  34. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine 1981;60:413-417.

  35. Gore I. Disseminated arteriolar and capillary platelet thrombosis. A morphological study of histogenesis. Am J Pathol 1950;25:155-160.

  36. Wallace DC, Lovric A, Clubb JS, Carseldine DB. Thrombotic thrombocytopenic purpura in siblings. Am J Med 1975;58:724-728.

  37. Hellman RM, Jackson DV, Buss DN. Thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome in HLA-identical siblings. Ann Intern Med 1980;93:283-287.

  38. Karlsberg RP, Lacher JW, Bartechi CE. Adult hemolytic-uremic syndrome: Familial variant. Arch Intern Med 1977;137:1155-1159.

  39. Kaplan et al. Hemolytic uremic syndrome in families, en Hemolytic Uremic Syndrome and Thrombotic thrombocytopenic purpura, editado por Kaplan BS, Trompeter RS, Moake JL, Marcel Dekker, New York, 1992. pp 213-225

  40. Levy GG, Nichols WC, Lian CE, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DS, Stark KR, Gruppo R, Sarode R, Shurin BS, Chandrasekaran V, Stabler PS, Sabio H, Bouhassira EE, Upshaw DJ, Ginsburg D, Han-Mou Tsai.Mutations in a member of the ADAMTS gene familiy cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-494.

  41. Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lammle B, Scheiflinger F. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003 Mar;120(5):821-4

  42. Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-celaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81:8-13.

  43. Cecere FA, Yoshinoya S, Pope RM. Fatal Thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus. Relationship to circulating immune complexes. Arthritis Rheum 1981;24: 550-555.

  44. Kwaan HC. Miscellaneous secondary thrombotic microangiopathy. Semin Hematol 1987;24:141-147.

  45. Rothfeld NF. Systemic lupus erythematosus, en Arthritis and Allied Conditions, editado por DJ McCarey, Lea and Febiger, Philadelphia, 1979. p 706

  46. Brittingham TE, Chaplin H. Attempted passive transfer of thrombotic thrombocytopenic purpura. Blood 1957;12:480-485.

  47. Harrington WJ, Minnich V, Holligsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38-43.

  48. Takahashi H, Hanano M, Wada K, et al. Circulating thrombomodulin in thrombotic thrombocytopenic purpura. Am J Hematol 1991;38:174-178.

  49. Lefevre P, George F, Durand JM, Sampol J, et al. detection of circulating endothelial cells in thrombotic thrombocytopenic purpura. Thromb Haemost 1993;69:522-526.

  50. Moake JL. von Willebrand factor abnormalitiies in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome, en Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura, editado por BS Kaplan, RS Trompeter, JL Moake, Marcel Dekker, New York, 1992. pp 459-471.

  51. Mannucci PM, Lombardi R, Lattuada A, et al. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood 1989;74:978-982.

  52. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle P, Brenner B, Krause M, Scharrer I, Aumman V, Mittler U, Solenthaler M, Lammle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.

  53. Tsai H, Chun-Yet L. Antibodies to Von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med.1998;339:1585-94

  54. Chintagumpala MM, Hurwitz RL, Moake JL, Mahoney DH, Steuber CP. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. J Pediatr 1992;120:49-53.

  55. Moore JC, Murphy WG, Kelton JG. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: An explanation for platelet aggregation in thrombotic thrombocytopenic purpura. Br J Haematol 1990;74:457-461.

  56. Lian ECY, Siddiqui FA, Jamieson GA, Tandon NN. Platelet agglutinating protein P37 causes platelet agglutination through its binding to membrane glycoprotein IV. Thromb Haemost 1991;65:102-107.

  57. Lian ECY, Mui PT, Siddiqui FA, Chiu AY, Chiu LL. Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G. J Clin Invest 1984;73:548-552.

  58. Wu KK. Role of prostacyclin in the pathogenesis and therapy of thrombotic thrombocytopenic purpura, en Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura, editado por BS Kaplan, RS Trompeter, JL Moake, Marcel Dekker, New York, 1992. pp 483-489.

  59. Gail RA. Management of thrombotic thrombocytopenic purpura (review). Br J Haematol.2000;109:496-507.

  60. Nabhan C, Kwaan HC. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am 2003 Feb;17(1):177-99.

  61. Han, Mou Tsai. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000;65:251-255.

  62. Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lammle B, Scheiflinger F.ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003;120(5):821-4.

  63. DiMichele D. and Neufeld EJ. Hemophilia. A New Approach to an Old Disease. Hematol/ Oncol Clin NA;12:1315-1349.

  64. Hoger Leon W. Hemophilia A. New Engl J Med. 1994;330:38-46.

  65. Lusher JM, Arkin S, Abildgard ChE, Schwartz RS. and the Kogenate Previously Untrated Patient Study Group. Recombinant factor VIII for the Treatment of Previously Untrated Patients with Hemophilia A. New Eng J Med. 1993;328:453-459.

  66. Schwartz RS, Abildgaard ChF, Aledort LM, Arkin S et al. Human Recombinant DNA-Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. New Eng J Med. 1990;323:1800-1805.

  67. Manucci Pier M. Ham-Wasserman Lecture. Hemophilia and Related Bleeding Disorders: A Story of Dismay and Success en: Broudy VC, Abkowitz JL, Vose JM (Eds). 2002:1-9.

  68. Kasper C. Protocols for the treatment of haemophilia and von Willebrand’s disease. Haemophilia 2000: 6: 84-93.

  69. Berliner S, Seligsohn G, Zivelin A. A relatively high frequency of severe (type III) von Willebrand’s disease in Israel. Br J Haematol 1986; 62: 535-43.

  70. Ginsburg D, Sadler J. von Willebrand’s disease: A database of point mutations, insertions, and deletions: For the Consortium of von Willebrand Factor Mutations and Polimorfism, and The Subcommittee on von Willebrand Factor and Standarization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemostas 1993; 69: 177-84.

  71. Lavergne J, Piao Y, Ribba P. Functional analysis of the Arg 91 Gln substitution on the factor VIII binding domain von Willebrand factor demonstrates variable phenotipic expression. Thromb Haemostas 1993; 70: 691-6.

  72. Meyer D, Girma J. von Willebrand factor: Structure and function. Tromb Haemostas 1993; 70: 99-104.

  73. Ginsburg D, Bowie W. Molecular genetics of von Willebrand’s disease. Blood 1992; 79: 2507-19.

  74. Miller C, Graham J, Goldin L. Genetics of classic von Willebrand’s disease. 1. Phenotipic variation within families. Blood 1979; 54: 117-35.

  75. Quintana-González S. Enfermedad de von Willebrand. Gac Med Mex 2000; 136 (Supl 2): 121-6.

  76. Benítez-Aranda H, Fernández G, Nieva-García B, Rodríguez-Zepeda MC, Juan-Shum, L, Bernaldez-Ríos R. Características clínicas de la enfermedad de von Willebrand. Revista Biomédica 2001; 12 (Supl 1): S46-S47.

  77. Budde U, Drewkw E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Sem Thromb Hemostas 2002; 28: 173-89.

  78. Ravelli A, Martín A. Antiphospholipid antibody syndrome in pediatric patients. Rheumatic Dis Clin North Am 1997:23 (3);657-676.

  79. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. report of an international. workshop. Arthritis Rheum 1999:42;1309-11.

  80. Godfrey T, D’Cruz D. Antiphospholipid syndrome: general features. En Kamashta MA Ed, Hughes Syndrome, Springer-Verlag London, Great Britain, 8-19, 2000.

  81. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med, 2002:346(10);752-63.

  82. Rand J. Molecular pathogenesis of the antiphospholipid syndrome. Circulation Res 2002:90;29-40.

  83. Fields R, Toubbeh H, Searles R, Bankhurst A. The prevalence of anticardiolipin antibodiesin a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989:16;623-5.

  84. Ginsber J, Wells P, Brill EP, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995:86;3685-91.

  85. Sutor AH, Uhl M. Diagnosis of thromboembolic disease during infancy and childhood. Sem Thromb Hemostas 1997:23;237-46.

  86. Kratz C, Mauz-KC, Kruck H, et al. Detection of antiphospholipid antibodies in children and adolescents. Pediatric Hematol Oncol 1998:15;325-32.

  87. Willems GM, Janssen MP, Comfurius P, et al. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membrabes. Biochemestry 2000:39;1982-9.

  88. Rand JH, Wu XX, Giensen P, et al. Antiphospholipid antibodies reduce annexin V and accelerate coagulation on cell membranes: mechanistic studies with a monoclonal antiphospholipid antibody. Trhomb Haemost 1999:82(suppl);1531a.

  89. Rand JH, Wu XX, Giesen P. A possible solution to the paradox of the “lupus coagulation”: antiphospholipid antibodies accelerate thrombin generation by inhibiting annexin V. Thromb Hemost 1999:82;1376-7.

  90. Rand JH, Wu XX, Andree HAM, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood 1998;92:1652-60.

  91. Wilson WA, Gharavi AE, Koike SA, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome : report of an international workshop. Arthtritis Rheum 1999:42;1309-11.

  92. Montecucco C, Caporali R. Hemocytopenias in antiphospholipid syndrome. En Kamashta MA Ed, Hughes Syndrome, Springer-Verlag London, Great Britain, 20-31, 2000.

  93. von Scheven E, Athreya BH, Rose CD, et al. Clinical Characteristics of antiphospholipid antibody syndrome in children. J Pediatrics 1996:129;339-45.

  94. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The primary and secondary antophospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994:112;682-98.

  95. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: an update. Thromb Haemost 1995:74;1185-90.

  96. Bick RL. The antiphospholipid-thrombosis syndromes: fact, fiction, confusion and controversy. Am J Clin Pathol 1993:100;477-80.

  97. Jilma B, kamath S, Lip GYH. ABC of antithrombotic therapy. Antithrombotic therapy in special circumstances. II-In children, thrombophilia and miscellaneous conditions. BMJ 2003:326;93-6.

  98. Olvera S. Epidemiología de la aterosclerosis coronaria. En: Posadas C. Dislipidemias y aterosclerosis. México, Interamericana-McGraw-Hill 1995:29-41.

  99. Chávez-Domínguez R. Factores de riesgo lipídicos. Epidemiología general de la aterosclerosis en México. En: Alcocer-Díaz-Barreiro L. Pautas en Cardiología Preventiva. México. Ediciones de la Sociedad Mexicana de Cardiología. Grupo MIND 1999:1-21.

  100. Antiplatelet Trialists´ Colaboration. Colaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.

  101. Izaguirre R, De Peña A, Barinagarrementería F, González H, Ramírez A, Ruiz JL. et al. Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjets with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Hemost 2002:8:169-177.

  102. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.

  103. Thaulow E, Erikssen, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healty men. Circulation 1991;84:613-7.

  104. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIaPlA1/PlA2 polymorphism with myocardial infarction. Am J Cardiol 2000;86:1000-5.

  105. Sinzinger H, Kaliman J, O’Grady J. Platelet lipoxygenase defect (Wien-Penzing defect) in two patients with myocardial infarction. Am J Hematol. 1993;36:202-5.

  106. Izaguirre R, Zaldívar H. El fibrinógeno como factor de riesgo cardiovascular. Arch Cardiol Mex 2003:73:7-10.

  107. Izaguirre R. Ruiz de Chávez A, Villavicencio R, Gómez A, Mar R, Spíndola MC et al. Variaciones en la hemostasia y fibrinolisis durante el tratamiento del infarto agudo del miocardio con activador tisular del plasminógeno. Arch Inst Cardiol Mex 1993;63:235-240.

  108. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR. North WR et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.

  109. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healty man. Arterioscler Throm 1994;14:54-9.

  110. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coaguylation factor VII and the risk of coronary heart disease in healty man. Arterioscler Throm Vasc Biol 1997;17:1539-44.

  111. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, von Willebrand factor and the risk of mayor ischaemic heart disease in the caerphilly heart study. Br J Haematol 1999;105:110-6.

  112. Burzotta F, Paciaroni K, De Stefano V, Chiusolo P, Manzoli A, Casorello I et al. Increased prevalence of the G20210A prothtombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J 2002:23:26-30.

  113. Eikelboom JW, Baker RI, Parsons R, Taylor RR, Van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost 1998;80:878-80.

  114. Avellone G, Di Garbo V, Di Raimondo D, Bono M, Abruzzese G, De Simone R, et al. Evaluation of resistance to activated protein C in myocardial infarction patients. Minerva Cardioangiol 2001;49:363-8.

  115. Gram J, Bladbjerg EM, Moller L, Sjol A, Jespersen J. Tissue-type-plasminogen activator and C-reactive protein in acute coronay hear disease. A nested case control study. J Inter Med 2000;247:205-12.

  116. Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D dimer, tissue plasminogen activator, plasminogen activator-inhibitor, and the risk of mayor ischaemic heart disease in the caerphilly. Thromb Haemost 1998;79:129-133.

  117. Pedersen OD, Munkvad S, Gram J, Kluft C, Jespersen J. Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. Eur Heart J 1993;14:785-9

  118. Bick RL. Disseminated intravascular coagulation and related syndromes. Semin Thromb Hemost 14:299;1988.

  119. Levi M, de Jonge E, van der Poll T, Tencate H. Disseminated intravascular coagulation. Thromb Haemost 82:695;1999.

  120. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 15:58;1989.

  121. Bick RL. Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin APPl Thrombosis/Hemostasis 1:3;1995.

  122. Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. BMJ 312:683;1996.

  123. Takahashi H, Tatewaki W, Wada K, Hanano M, Shibata A. Thrombin vs plasmin generation in disseminated intravascular coagulation associated with various underlying dissorders. Am J Hematol 33:90;1990.

  124. Tapper H, Herwald H. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood 96:2329;2000.

  125. Minnema MC Chang ACK, Jansen PM, et al. Recombinant human antithombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95:1197;2000.

  126. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflamatory response to endotoxin? Blood 95:1113;2000.

  127. Barbui T, Finazzi G, Falanga A. The impact of All-trans-Retinoic Acid on the coagulopathy of acute promyelocytic leukemia. Blood 91:3093;1998.

  128. Corrigan JJ, Ray WL, May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med 279:851;1968.

  129. Goldenfarb PB, Zucker S, Corrigan JJ, Cathey MH. The coagulation mecanism in acute bacterial infection. Br J Haematol 18:643;1970.

  130. Baker WF. Clinical aspects of disseminated intavascular coagulation: A clinician’s point of view. Semin Thromb Hemost 15:1;1989.

  131. Deykin D. The clinical challenge of disseminated intravascular coagulation N Engl J Med 283:636;1970.

  132. Briones LR, Dorantes S. Coagulación intravascular diseminada. Bol. Med. Hosp. Infant. Mex 33:245;1976.

  133. Paredes-Aguilera R. López N., Taboada Meza C y cols. Púrpura fulminante idiopática. Bol. Med Hosp. Infant Mex 51:717;1994.

  134. Paredes-Aguilera R. Macías-Cruz D, Reynes-Manzur J y cols. Púrpura fulminante recurrente. Bol. Med Hosp. Infant Mex 51:717;1994.

  135. Corrigan JJ, Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation: Effect on mortality and correction of hemostatic defects. N Engl J Med 283:778;1970.

  136. Feinstein DT. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 14:351;1988.

  137. Francis JL, Biggerstaff, Amirkhosravi A. Hemostasis and malignancy. Sem Tromb Hemost 1998;2:93-109

  138. Trousseau A. Phlegmasia alba dolens. In: Anonymous. Clinique Medicale de l’Hotel de Paris. The New Sydenham Society,London 1865;3:94-96.

  139. Billroth T. Lectures on surgical pathology and therapeutics. A handbook for students and practitioners, ed. 8.London, New Sydenham Society, 187, p 1877-1878.

  140. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 2001;106:18-24.

  141. Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, Julian J. The ocurrence of subsequent malignancy in patients presenting with deep vein thrombosis: Results from a historical cohort study. Thromb Haemost 1998;79:19-22.

  142. Agnelli G. Venous thromboembolism and cancer: a two way clinical association. Thromb Haemost 1998;78(1):117-20.

  143. Prins MH, Hettiarachchi RJK, Lensing AWA, Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see?. Thromb Haemost 1998;78(1):121-5.

  144. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133.

  145. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001;106:6-12.

  146. Sack GH, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Medicine 1977; 56:1-37.

  147. Cantwell BMJ, Carmichael J, Ghani SE, Harris AL. Thrombosis and throemboemboli in patients with lymphoma during cytotoxic chemotherapy. BMJ 1998;297:179-180.

  148. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Sem thromb Haemost 1998;2:93-109.

  149. Lebeau B, Chastang C, Brechot JM. Subcutaneous heparin treatment increases survival in small cell lung cancer “Petites cellules” group. Cancer 1994;74:38-45.

  150. Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1998;78(1):126-32.

  151. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1998;78(1):141-4.

  152. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematologica 2001;106:25-32.

  153. Falanga A, Consonni R, Marchetti M, Locatello G, Garattini E, Passerini CG, Gordon SG, Barbui T. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998;92:143-151.

  154. Martin DM, Boys WG, Ruf W. Tissue factor: molecular recognition and cofactor function. FASEB 1995;10:852-859.

  155. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasic prognostic relevance and target for therapy. Thromb Haemost 1998;78(1):285-96.

  156. Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF-VIIa complex in the cellular initiation of coagulation. Thromb Haemost 1997;78(1):401-5.

  157. Banner DW. The factor VIIa/ tissue factor complex. Thromb Haemost 1997;78(1):512-5.

  158. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997;78(1):471-7

  159. Semeraro N, Colucci M. Tissue factor in heatlh and disease. Thromb Haemost 1997;78(1):759-64.

  160. Osterud B. Tissue factor : a complex biological role . Thromb Haemost 1997;78(1):765-69.

  161. Carmeliet P, Collen D. Tissue factor. Int J Biochem Cell Biol 1998;30(6):661-67.

  162. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996;77(9):1877-83.

  163. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expresion correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82(8):1101-4.

  164. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastasic potential of colorectal cancer. Thromb Haemost 1998;80:894-98.

  165. Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru K, Yoshizawa Y. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999;79:472-77.

  166. Koomagi R, Volm M. Tissue factor expression in human non-small-cell-lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;79:19-22.

  167. Semeraro N, Montemurro P, Giordano P, Santoro N, De Mattia D, Colucci M. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma. Thromb Haemost 1994;72(1):54-7.

  168. Ruco LP, Pittiglio M,Dejana E, Baroni CD. Vascular activation in the histopathogenesis of Hodgkin’s disease: potential role of endothelial tissue factor in intravascular thrombosis and necrosis. J Pathol 1993;171(2):131-6.

  169. Adida C, Ambrosini G, Plescia J, Crotty PL, Costa J, Altieri DC. Protease receptors in Hodgkin’s disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells. Blood 1996;88:1457-64.

  170. Shibakura M, Koyama T, Saito T, Shudo K, Miyasaka N, Kamiyama R, Hirosawa S. Anticoagulant effects of synthetic retinoids mediated via different receptors on human leukemia and umbilical vein endothelial cells. Blood 1987;90(4):1545-51.

  171. Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, Gordon SG, Barbui T. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic-acid in acute promielocytic leukemia. Blood 1998;92(1):143-51.

  172. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost 1997;78:1-6.

  173. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Wheeler HB. Prevention of venous thromboembolism. Chest 2001;119;132S-175S.

  174. Lobato-Mendizabal E, Majluf-Cruz A. Trombofilia, tromboembolia y el uso de las heparinas no fraccionadas y de bajo peso molecular. Rev Invest Clin 2000;56:346-365.

  175. Martínez Murillo C, Quintana González S, Ambriz Fernández R, Hernández Paula M. El problema trombótico. Hematología 2000;1:17-20.

  176. Lens D, Otero AM. Diagnóstico molecular de factores protrombóticos: primeros casos de factor V Leiden y protrombina G20210A en Uruguay. Revista Médica de Uruguay 2000;16:39-44.

  177. Guba SC, Fonseca V, Fink LM. Hyperhomocysteinemia and thrombosis. Semin Thromb Haemost 1999;25:291-309.

  178. Ruiz Argüelles GJ, González Estrada S, Garcés Eisele J, Ruiz Argüelles A. Primary thrombophilia in Mexico: A prospective study. Am J Hematol 1999;60:1-5.

  179. Ruiz Arguelles GJ, Garcés Eisele J, Reyes Nuñez V, Ramirez Cisneros FJ. Primary thrombophilia in Mexico II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenete-trahydrofolate reductasa C677T polymorphism in thrombophilic mexican mestizos. Am J Hematol 2001;66:28-31.

  180. Barinagarremenetería F, Cantú-Brito C, De La Peña A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. Stroke 1994;25:287-290.




2020     |     www.medigraphic.com